Currently, no vaccine exists that can cure HIV, the virus that causes AIDS. Today, 36.7 million people are living with HIV/AIDS. Despite progress with antiretroviral therapy and other research dedicated to stopping this disease, there still is a dire need for effective and reliable methods of prevention. As Fenway Health continues to commit to the work of treating and preventing HIV/AIDS, The Fenway Institute is excited to announce the start of two new research trials, HVTN 120 and 124. These studies will be testing the tolerability and human immune response to experimental DNA, gene, and protein-based vaccines.
Participants that are eligible for HVTN 120 are people between the ages of 18 and 40 who are healthy, HIV-uninfected, and will be living in Boston for the next 18 months. Participants will attend 12 visits over 18 months, including visits that involve injections and regular follow-up visits. Participants will also have a post-study health contact one month after the last vaccination. Volunteers will receive up to $1200 compensation for their time.
Participants that are eligible for HVTN 124 are people between the ages 18 and 50 who are healthy, HIV-uninfected, and will be living in Boston for 14 months. Participants will attend 14 clinical visits over 14 months, these including both visits with injections and regular follow-up visits. Participants in this study will also have a post-study health contact one month after the last vaccination is received. Volunteers will receive up to $1,475 compensation for their time.
For more information and to see if you would be eligible for the study, please fill out the prescreener here. Or call 617.927.6450 or email BeTheChange@fenwayhealth.org.
Want to receive email updates about what’s happening at Fenway Health and AIDS Action? Sign up here.